Perioperative Durvalumab in Bladder Cancer
Bladder Cancer

New Indication: Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma

2023-06-07

  • Study

    Phase II, open-label, single-arm study
    Cisplatin-fit resectable cT2-T4a,cN0-N1 MIUC
    GC+ Durvalumab followed by surgery followed by Durvalumab maintenance

  • Efficacy

    2-year EFS: 76% [62-85]
    3-year EFS: 73% [59-83]
    3-year OS: 81% [67-89]
    cPR: 33% [17 of 52 pts]

  • Safety

    Grade≥ 3: Neutrophenia (21%), thrombocytopenia (21%), anemia (18%)

    • J Clin Oncol AUG 17; 2023

    Cathomas Richard et al. Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17

    http://doi.org/10.1200/JCO.23.00363

    Reviewed by Elvin CHALABİYEV, MD on SEP 10, 2023